Education
About Us
Working with TipRanks
Follow Us
Alterity Therapeutics Ltd. (AU:ATH)
ASX:ATH
ATH Stock Chart & Stats
AU$0.01
>-AU$0.01(-10.00%)
At close: 4:00 PM EST
AU$0.01
>-AU$0.01(-10.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume25.42M
Average Volume (3M)16.33M
Market Cap
AU$87.00M
Enterprise ValueAU$27.09M
Total Cash (Recent Filing)AU$49.20M
Total Debt (Recent Filing)AU$163.91K
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding10,875,416,000
10 Day Avg. Volume24,202,939
30 Day Avg. Volume16,327,471
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.51
Price to Sales (P/S)11.76
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.01Price Target Upside0.00%
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$2.26M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA sustained 46% revenue increase indicates expanding commercial or grant-supported activity and validates aspects of the business model. Over 2–6 months this strengthens bargaining power for partnerships or non-dilutive funding and reduces near-term dependence on emergency capital raises.
Low Financial LeverageMinimal leverage materially lowers solvency risk and preserves flexibility to finance R&D via equity or partnerships. This durable balance-sheet strength supports multi-stage clinical programs and reduces interest burden, improving resilience through lengthy development cycles.
Focused Pipeline In NeurodegenerationA concentrated small-molecule program targeting neurodegenerative diseases aligns with strong, long-term unmet medical need and potential for high-value partnerships or licensing. Focused R&D can drive efficient allocation of limited resources and clearer value inflection points.
Bears Say
Negative ProfitabilityConsistent negative margins reflect that revenue currently fails to cover operating costs, a structural issue for pre-commercial biotechs. Over months this pressures cash reserves, limits reinvestment capacity, and makes the company reliant on external funding to sustain development programs.
Weak Cash GenerationNegative operating and free cash flow with steep FCF decline signal ongoing burn and poor cash conversion. This reduces runway, increases the likelihood and frequency of capital raises, and constrains strategic flexibility for multi-stage clinical commitments over the next several months.
Reliance On External FinancingBeing pre-commercial and reliant on equity issuances and external funding is a durable business risk: it exposes the company to dilution, timing of capital markets, and changing partner interest, all of which can materially affect program continuity and strategic options.
Alterity Therapeutics News
ATH FAQ
What was Alterity Therapeutics Ltd.’s price range in the past 12 months?
Alterity Therapeutics Ltd. lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Alterity Therapeutics Ltd.’s market cap?
Alterity Therapeutics Ltd.’s market cap is AU$87.00M.
When is Alterity Therapeutics Ltd.’s upcoming earnings report date?
Alterity Therapeutics Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 362 days.
How were Alterity Therapeutics Ltd.’s earnings last quarter?
Alterity Therapeutics Ltd. released its earnings results on Feb 25, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of AU$0 by AU$0.
Is Alterity Therapeutics Ltd. overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd.’s price is currently same.
Does Alterity Therapeutics Ltd. pay dividends?
Alterity Therapeutics Ltd. does not currently pay dividends.
What is Alterity Therapeutics Ltd.’s EPS estimate?
Alterity Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alterity Therapeutics Ltd. have?
Alterity Therapeutics Ltd. has 10,875,416,000 shares outstanding.
What happened to Alterity Therapeutics Ltd.’s price movement after its last earnings report?
Alterity Therapeutics Ltd. reported an EPS of AU$0 in its last earnings report, expectations of AU$0. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ATH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.01 (0.00% )
AU$0.01 (0.00% )
Blogger Sentiment
Bullish
AU:ATH Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-42.68%
Trailing 12-Months
Asset Growth
134.94%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd.
Alterity Therapeutics (ATH) is a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, primarily targeting conditions such as Parkinson's disease and Alzheimer's disease. The company leverages its proprietary drug discovery platform to identify and develop small molecule therapies aimed at modifying disease progression and improving patient outcomes. Alterity is dedicated to advancing its clinical programs and expanding its pipeline of novel treatments to address significant unmet medical needs in the neurology sector.
ATH Stock 12 Month Forecast
Average Price Target
AU$0.01
▲(0.00% Upside)
Technical Analysis
Imugene
―
Paradigm Biopharmaceuticals
―
EZZ Life Science Holdings Ltd.
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---